Study finds GLP-1 drugs can help curb SUDs
A study published by BMJ found that glucagon-like peptide-1 (GLP-1) drugs could help reduce the risk of various substance use disorders, including for alcohol, cannabis, nicotine, cocaine and opioids. The study examined records of more than 600,000 patients from the Department of Veterans Affairs who had Type 2 diabetes and took a GLP-1 or a sodium-glucose cotransporter-2 inhibitor, or SGLT2, for treatment. Additionally, the study found that people with pre-existing SUDs who took GLP-1 drugs had reduced risks of SUD-related emergency room visits, hospital admissions, overdose, suicide and death.
Related News Articles
Headline
The Substance Abuse and Mental Health Services Administration announced March 6 that it will award $69.1 million in grants for mental health and suicide…
Headline
The Department of Health and Human Services Office for Civil Rights Feb. 13 announced the launch of a program to implement and enforce statutory and regulatory…
Headline
The White House issued an executive order Jan. 29 to address substance use and addiction. The order establishes the White House Great American Recovery…
Headline
The Substance Abuse and Mental Health Services Administration has released a guide to improve coordination between 988 lifeline and 911 emergency services. It…
Headline
The latest estimates on overdose deaths released yesterday by the Centers for Disease Control and Prevention show that as of August 2025, deaths fell…
Headline
A Centers for Disease Control and Prevention report found a drastic increase in alcohol-related emergency department visits from 2003-2004 to 2021-2022. The…